US 12,076,369 B2
Immunoregulatory molecules and uses therefor
Maria Carola Garcia De Vinuesa De La Concha, Lyons (AU); and Paula Carolina Cecilia Gonzalez-Figueroa, Acton (AU)
Assigned to The Frances Crick Institute Limited, London (GB)
Appl. No. 16/642,769
Filed by The Frances Crick Institute Limited, London (GB)
PCT Filed Aug. 31, 2018, PCT No. PCT/AU2018/050944
§ 371(c)(1), (2) Date Feb. 27, 2020,
PCT Pub. No. WO2019/040994, PCT Pub. Date Mar. 7, 2019.
Claims priority of application No. 2017903538 (AU), filed on Sep. 1, 2017.
Prior Publication US 2021/0196792 A1, Jul. 1, 2021
Int. Cl. A61K 38/18 (2006.01); A61K 47/60 (2017.01)
CPC A61K 38/185 (2013.01) [A61K 47/60 (2017.08)] 14 Claims
 
1. A method for inhibiting plasma cell (PC) differentiation in a subject having an IgE-mediated disorder, wherein the IgE-mediated disorder is not an autoreactive B cell disorder, the method comprising administering a neuritin polypeptide to the subject, wherein a B cell of the subject is contacted with the neuritin polypeptide, to thereby inhibit PC differentiation in the subject, wherein the neuritin polypeptide is a polypeptide comprising an amino acid sequence set forth in any one of SEQ ID NO: 2, 4 and 6.